drugset / Trial / NCT00219037

Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension

NCT00219037

Phase 3 Completed 1955 enrolled Novartis
RandomizedParallel-groupSingle-blindTreatment

Summary

Assess the long-term safety and tolerability of aliskiren, with the optional addition of HCTZ, in patients with essential hypertension, to ensure long term blood pressure control and protect against end organ damage.

Timeline

Start
2004-06
Primary completion
2005-10
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 150 mg Oral
Subject Aliskiren Small molecule 300 mg Oral